Request Demo
Last update 17 Apr 2025
NN-3201
Last update 17 Apr 2025
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms NN-3201 |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors, c-Kit inhibitors(Stem cell growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization  Novelty Nobility, Inc.Startup |
Active Organization Novelty Nobility, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Boost your research with our ADC technology data.
login
or
Related
1
Clinical Trials associated with NN-3201NCT06805825
A Phase 1 Dose Escalation and Expansion Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects with Advanced And/or Metastatic Solid Tumors Known to Express C-Kit
100 Clinical Results associated with NN-3201
Login to view more data
100 Translational Medicine associated with NN-3201
Login to view more data
100 Patents (Medical) associated with NN-3201
Login to view more data
100 Deals associated with NN-3201
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenoid Cystic Carcinoma | Phase 1 | United States | Novelty Nobility, Inc.Startup | 03 Feb 2025 |
| Extensive stage Small Cell Lung Cancer | Phase 1 | United States | Novelty Nobility, Inc.Startup | 03 Feb 2025 |
| Renal Cell Carcinoma | Phase 1 | United States | Novelty Nobility, Inc.Startup | 03 Feb 2025 |
| Uveal Melanoma | Phase 1 | United States | Novelty Nobility, Inc.Startup | 03 Feb 2025 |
| Gastrointestinal Stromal Tumors | Phase 1 | United States | Novelty Nobility, Inc.Startup | 03 Feb 2025 |
| Small Cell Lung Cancer | Phase 1 | South Korea | Novelty Nobility, Inc.Startup | - |
| Acute Myeloid Leukemia | Preclinical | South Korea | Novelty Nobility, Inc.Startup | 27 Jul 2022 |
| Philadelphia chromosome positive chronic myelogenous leukemia | Preclinical | South Korea | Novelty Nobility, Inc.Startup | 27 Jul 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free